Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

Nirsevimab, a monoclonal antibody with an extended half‐life, is approved for the prevention of respiratory syncytial virus (RSV) disease in all infants in Canada, the EU, Great Britain, and the USA. A population pharmacokinetics (PK) model was built to describe the PK of nirsevimab in preterm and t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2024-05, Vol.64 (5), p.555-567
Hauptverfasser:	Clegg, Lindsay, Freshwater, Ed, Leach, Amanda, Villafana, Tonya, Hamrén, Ulrika Wählby
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacokinetics Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - administration & dosage Antiviral Agents - pharmacokinetics Body Weight Clinical trials Dosage Female Heart diseases Humans Infant Infant, Newborn Infant, Premature Infants Lung diseases Male Models, Biological Monoclonal antibodies nirsevimab Pharmacokinetics population PK model preterm infants Respiratory syncytial virus Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!